4:10 PM ET
8-K
Business Update
Larimar Therapeutics Business Update
Larimar Therapeutics has completed its rolling Biologics License Application (BLA) submission to the FDA seeking accelerated approval for nomlabofusp in Friedreich’s ataxia. The filing also includes a preliminary cash balance of $128.7 million as of September 30, 2026, and an updated corporate presentation for investor meetings.
- Counterparty
- FDA